Reversible Cerebral Vasoconstriction Syndrome with Hyperthyroidism.

Intern MedFeb 1, 2026 (epub)
Case ReportEndocrinologyNeurology

Daisuke Kudo, Masaki Fujino, Osamu Tao

✦ AI-curated · Sources linked

Case in brief

A 55-year-old woman presented with recurrent thunderclap headaches precipitated by bathing, showering, and the Valsalva maneuver. Laboratory testing showed hyperthyroidism, and brain MRI demonstrated convexity subarachnoid hemorrhage and cerebral arterial vasospasm. She was diagnosed with reversible cerebral vasoconstriction syndrome (RCVS) alongside hyperthyroidism. The report discusses the possible association between RCVS and thyroid function; the abstract does not describe treatment or clinical resolution.

What made this case unusual

RCVS occurred in a patient with hyperthyroidism, an association the authors note has received limited attention in the literature.

Diagnostic / clinical pearl

Recurrent thunderclap headache with convexity subarachnoid hemorrhage and cerebral arterial vasospasm should prompt consideration of RCVS; this case also documents coexisting hyperthyroidism.

Source

PubMed · PMID 41621871

Published in Intern Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.